Role of complement inhibitors in improving lung transplant outcomes:a complement to existing therapies
10.12464/j.issn.1674-7445.2025183
- VernacularTitle:补体抑制剂在改善肺移植预后中的作用:对现有疗法的补充
- Author:
Yichen WU
1
;
Feng LIU
1
Author Information
1. 江苏无锡 214000,南京医科大学附属无锡人民医院胸外科
- Publication Type:Journal Article
- Keywords:
Lung transplantation;
Complement inhibitor;
Primary graft dysfunction;
Antibody-mediated rejection;
Chronic lung allograft dysfunction;
C5 inhibitor;
Eculizumab;
C1 esterase inhibitor
- From:
Organ Transplantation
2025;16(5):792-797
- CountryChina
- Language:Chinese
-
Abstract:
Lung transplantation is the only effective treatment for end-stage lung diseases.However,its long-term prognosis is affected by early and late complications,such as primary graft dysfunction,antibody-mediated rejection,and chronic lung allograft dysfunction.In recent years,the central role of the complement system in these pathological processes has gradually gained attention.As a novel immunomodulatory strategy,complement inhibitors are still in the exploratory phase in lung transplantation.Therefore,this article reviews the pathological mechanisms of the complement system in primary graft dysfunction,antibody-mediated rejection,and chronic lung allograft dysfunction.Combined with existing clinical cases,it analyzes the potential role and limitations of complement inhibitors in improving lung allograft function and proposes future research directions and suggestions.The aim is to provide a reference for the precise intervention of lung transplant complications and the improvement of lung transplant outcomes.
